Xenon Pharmaceuticals Inc (XENE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

200 - 3650 GILMORE WAY BURNABY, BRITISH COLUMBIA, CANADA V5G 48W

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapeutics for rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.

Data based on most recent fiscal year report
Market Cap87.3 Million Shares Outstanding18 Million Avg Volume136.571 Thousand
1-Yr BETA vs S&P TR1.163 Current Ratio10.99 Quick Ratio10.99
View SEC Filings from XENE instead.
Q3 2019 All Institutions Hedge Funds 1
To trade XENE now:
Filers who had this stock in their top 10: 2 1 (0.1%)
13F Filers holding this stock: 53 17 (1.78%)
Aggregate 13F shares on 09/30/2019: 15.302 Million 10.214 Million
Aggregate 13F shares on 06/30/2019: 17.563 Million 10.418 Million
Percent change: -12.87% -1.96%
Funds creating new positions: 4
Funds Adding to an existing position: 11 3
Funds closing out their position: 9 2
Funds reducing their position: 18 6
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding XENE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
658,531 2019-11-14 0

HAYDEN MICHAEL R

  • Director
77,728 2019-11-11 3

PIMSTONE SIMON N. CEO

  • Officer
  • Director
274,582 2019-09-20 2

HOLLER FRANK A

  • Director
118,955 2019-09-19 3

TARNOW MICHAEL M

  • Director
0 2019-09-16 3

PATOU GARY

  • Director
0 2019-09-16 2

MORTIMER IAN PRESIDENT & CFO

  • Officer
0 2019-09-16 1

ROBIN SHERRINGTON EVP, STRATEGY & INNOVATION

  • Officer
0 2019-09-16 2

SCHELLER RICHARD H

  • Director
0 2019-09-16 1

GANNON STEVEN

  • Director
0 2019-09-16 1

EMPFIELD JAMES R. SVP, DRUG DISCOVERY

  • Officer
0 2019-09-16 1

SVORONOS DAWN

  • Director
0 2019-09-16 1

AYCARDI-FONSECA ERNESTO CMO

  • Officer
0 2019-09-16 1

AZAB MOHAMMAD

  • Director
57,561 2019-09-13 2

BRIDGER GARY

  • Director
0 2019-03-13 0

STEIN EVAN A.

  • Director
0 2019-01-29 0

COHEN CHARLES J. VP, BIOLOGY

  • Officer
6,550 2018-12-11 1

GOLDBERG Y. PAUL SVP, CLINICAL DEVELOPMENT

  • Officer
0 2017-10-23 0

WINQUIST RAYMOND HEAD, TRANSLATIONAL RESEARCH

  • Officer
1,000 2017-08-18 0

EVANS JOHNSTON L

  • Director
0 2015-05-04 0

CORRAINI KAREN G. GEN. COUNSEL & CORP. SECRETARY

  • Officer
0 2015-03-17 0

MX ASSOCIATES, LLP

  • 10% Owner
No longer subject to file 2014-12-31 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments